Currently, we do not have any Epilepsy or Seizure trials open to enrollment. Trials are added on an ongoing basis. Please check back at a later date.
Title: An open-label, follow-up trial to evaluate the long-term safety and efficacy of brivaracetam (up to 200mg/day) used as adjunctive treatment at a flexible dose up to a maximum of 200mg/day in subjects in subjects suffering from partial onset seizures Principal Investigator: Ritu Bagla, MD Sponsor: UCB, Inc. Summary: The purpose of this study is to evaluate the long-term safety and efficacy of brivaracetam as an adjunctive treatment (maximum dose 200 mg/day) for partial onset seizures.Title: An Open-Label, Multinational, Multi-center, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam, Used at a Flexible Dose up to a Maximum of 200 mg/day, in Subjects Aged 16 Years or Older Suffering From Epilepsy Principal Investigator: Ruti Bagla, MD Sponsor: UCB, Inc. Summary: This is a phase III, therapeutic confirmatory long-term follow-up, multinational, multi-center, non-comparative, open-label and single arm trial sponsored by UCB. The primary objective is to evaluate the long-term safety and tolerability of brivaracetam at individualized doses with a maximum of 200 mg/day in subjects suffering from epilepsy.
RESEARCH IN NEUROLOGY
The American Heart Association/American Stroke Association's Get With The Guidelines program has again awarded Lahey Clinic’s stroke service the Stroke Gold Performance Achievement Award.